Latest news with #H.C. Wainwright
Yahoo
3 days ago
- Business
- Yahoo
Corcept Therapeutics Advances Pipeline Fueling Growth With Controlled Risk
Corcept Therapeutics Incorporated (NASDAQ:CORT) is one of the . The company completes a key drug study and has submitted a new drug application to the U.S. FDA. A biologist in a lab coat studying a culture of cells to find a cure for metabolic disorders. Corcept Therapeutics Incorporated (NASDAQ:CORT) is a California-based company specializing in cortisol modulation through glucocorticoid receptor antagonists. The company's flagship drug, Korlym®, treats Cushing's syndrome and features a growing pipeline of over 30 clinical-stage compounds targeting endocrinology, oncology, metabolism, and neurology. Corcept Therapeutics Incorporated (NASDAQ:CORT) announced the completion of its Phase 1 study involving the examination of the effects of itraconazole on the pharmacokinetics and safety of dazucorilant in healthy adults. The trial involved single-dose dazucorilant and repeated itraconazole doses. The study ran from May 31, 2024, to June 29, 2025, and is now concluded. The findings are expected to optimize drug interaction safety. Additionally, after gaining positive results from the Phase 3 ROSELLA trial and earlier Phase 2 studies, Corcept Therapeutics Incorporated (NASDAQ:CORT) has submitted a new drug application to the U.S. FDA for relacorilant. The data from the earlier studies indicated that relacorilant combined with nab-paclitaxel highly improves progression-free and overall survival compared to nab-paclitaxel alone. Analysts, including Piper Sandler and H.C. Wainwright, are maintaining their Buy rating on the stock, with a price target of $131 and $145, respectively. In addition to the rating, Corcept Therapeutics Incorporated (NASDAQ:CORT) increases its appeal by offering a rare low-risk, high-growth appeal, with a beta of 0.20 and projected EPS growth of 69.48%. While we acknowledge the potential of CORT as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: 10 Metal Stocks with Insider Buying in 2025 and 10 Energy Stocks with Insider Buying in 2025 Disclosure. None. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
7 days ago
- Business
- Yahoo
HIVE Digital Technologies Ltd. (HIVE) Rated as a Buy on Crypto and HPC Opportunities
HIVE Digital Technologies Ltd. (NASDAQ:HIVE) is one of the top AI stocks with huge upside potential. On July 21, H.C. Wainwright reiterated a 'Buy' rating on the stock and a $6 price target. The research firm remains optimistic about the company's long-term prospects, buoyed by its rapid hash rate expansion and growth in the high-performance computing business. A close-up of hands typing code to facilitate the exchange of Ethereum and Ethereum Classic. The company has more than doubled its deployed hash rate in less than six months to 12.5 EH/s at its data center in Paraguay. Hive Digital management has already embarked on an ambitious plan to strengthen the hash rate to 18 EH/s by the end of August and 25 EH/s by November. The expansion positions it to ramp up bitcoin mining operations to capitalize on the soaring prices. Hive Digital has also acquired a 7.2 MW data center in Toronto as it seeks to expand its high-performance computing capacity by 3.5 times. The expansion is expected to enhance the company's annualized HPC revenues to approximately $100 million upon full deployment. Initially focused on cryptocurrency mining, HIVE Digital Technologies Ltd. (NASDAQ:HIVE) is transitioning into the AI sector by leveraging its existing infrastructure of powerful servers. Its expertise in running high-performance computing infrastructure positions it to provide green infrastructure solutions for the AI revolution. While we acknowledge the potential of HIVE as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: 10 Best Chemical Stocks to Buy According to Billionaires and 7 Most Undervalued Pot Stocks To Buy According To Analysts. Disclosure: None. This article is originally published at Insider Monkey.
Yahoo
7 days ago
- Business
- Yahoo
H.C. Wainwright Reiterates Buy Rating on Yatra Online (YTRA) Stock
Yatra Online, Inc. (NASDAQ:YTRA) is one of the Best Indian Stocks to Buy for Next 5 Years. Analyst Scott Buck of H.C. Wainwright reiterated a 'Buy' rating on the company's stock, while retaining a price objective of $3.00. The analyst's rating is backed by a combination of factors demonstrating Yatra Online, Inc. (NASDAQ:YTRA)'s robust performance and growth potential. The company showcased significant strength in its corporate travel and MICE (Meetings, Incentives, Conferences, and Exhibitions) segments, offsetting the weaker trends in the B2C sector. A passenger gazing out the airplane window, taking in the sights of her journey. Yatra Online, Inc. (NASDAQ:YTRA) onboarded 35 new corporate clients in Q4 2025, fueling its annual billing potential significantly. The acquisition of Globe Travels strengthened Yatra Online, Inc. (NASDAQ:YTRA)'s position, which enabled it to target for top-three spot in the broader Indian MICE market ahead of schedule. The growth opportunities in this market offer the company a unique opportunity to tap more market share. Yatra Online, Inc. (NASDAQ:YTRA) ended FY 2025 on a strong footing, delivering revenue for 3 months to March 31, 2025 of INR2,192.5 million (US$25.7 million), up by 114.0% YoY. This was aided by growth in the company's MICE business and the inorganic contribution from the Globe Travels acquisition. Moving forward, robust corporate client acquisition, growth in the MICE segment, and ongoing investment in its proprietary technology platform, which includes AI-powered personalization and booking tools, place it well for the next growth phase. Yatra Online, Inc. (NASDAQ:YTRA) operates as an online travel company. It is based in Gurugram, India. While we acknowledge the potential of YTRA as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: 13 Cheap AI Stocks to Buy According to Analysts and 11 Unstoppable Growth Stocks to Invest in Now Disclosure: None. This article is originally published at Insider Monkey. Sign in to access your portfolio
Yahoo
22-07-2025
- Business
- Yahoo
Sarepta falls after gene therapy maker pauses Elevidys shipments in US
(Reuters) -Shares of Sarepta Therapeutics fell nearly 7% on Tuesday after the company agreed to comply with the U.S. health regulator's request to pause all shipments of its gene therapy Elevidys in the United States. The U.S. Food and Drug Administration on Friday asked Sarepta to voluntarily halt shipments of the gene therapy, but the company refused to do so and said it would continue making the treatment available to ambulatory patients. But Sarepta has now voluntarily and temporarily paused all shipments of the therapy, effective end of Tuesday. The company said the decision would allow it to respond to requests from the FDA and maintain a positive relationship with the agency. "Though Sarepta claims its pause in shipments was voluntary, we think the company moved preemptively — bracing for an inevitable FDA mandate to pull the drug," said H.C. Wainwright analyst Mitchell Kapoor. Shares of Sarepta fell 6.9% to $12.40 in early trading on Tuesday. "Sarepta's decision to comply was a capitulation after recognizing that the fight with the FDA was not winnable and that the agency would have strong-armed Sarepta into removing Elevidys with a formal demand," Kapoor added. Investor concerns regarding the use of the company's treatments have been heightened after the company on Friday disclosed that another patient who had received its experimental gene therapy died from acute liver failure, marking the third death this year. The company's shares have plummeted 89% so far this year. On Monday, Children's Hospital Los Angeles said it had paused usage of Elevidys in all patients with muscular dystrophy. The FDA's initial request had likely heightened the pressure on physicians to pause treatments, which could also have been a driving factor in Sarepta's decision, William Blair analyst Sami Corwin said. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Reuters
22-07-2025
- Business
- Reuters
Sarepta falls after gene therapy maker pauses Elevidys shipments in US
July 22 (Reuters) - Shares of Sarepta Therapeutics (SRPT.O), opens new tab fell nearly 7% on Tuesday after the company agreed to comply with the U.S. health regulator's request to pause all shipments of its gene therapy Elevidys in the United States. The U.S. Food and Drug Administration on Friday asked Sarepta to voluntarily halt shipments of the gene therapy, but the company refused to do so and said it would continue making the treatment available to ambulatory patients. But Sarepta has now voluntarily and temporarily paused all shipments of the therapy, effective end of Tuesday. The company said the decision would allow it to respond to requests from the FDA and maintain a positive relationship with the agency. "Though Sarepta claims its pause in shipments was voluntary, we think the company moved preemptively — bracing for an inevitable FDA mandate to pull the drug," said H.C. Wainwright analyst Mitchell Kapoor. Shares of Sarepta fell 6.9% to $12.40 in early trading on Tuesday. "Sarepta's decision to comply was a capitulation after recognizing that the fight with the FDA was not winnable and that the agency would have strong-armed Sarepta into removing Elevidys with a formal demand," Kapoor added. Investor concerns regarding the use of the company's treatments have been heightened after the company on Friday disclosed that another patient who had received its experimental gene therapy died from acute liver failure, marking the third death this year. The company's shares have plummeted 89% so far this year. On Monday, Children's Hospital Los Angeles said it had paused usage of Elevidys in all patients with muscular dystrophy. The FDA's initial request had likely heightened the pressure on physicians to pause treatments, which could also have been a driving factor in Sarepta's decision, William Blair analyst Sami Corwin said.
